#1 Clinical Trials Search in Europe

Cusatuzumab

Cusatuzumab is an experimental drug being studied in clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These trials are evaluating cusatuzumab alone and in combination with other drugs to determine its safety and effectiveness in patients who are not eligible for intensive chemotherapy. The studies aim to assess how well cusatuzumab works compared to standard treatments in improving outcomes for patients with these blood cancers.

Table of Contents

What is Cusatuzumab?

Cusatuzumab is an experimental drug being studied for the treatment of certain blood cancers. It is also known by several other names, including JNJ-74494550, ARGX-110, and OV-1001[1][2][3][4][5]. This drug is a type of medicine called a monoclonal antibody, which is a laboratory-made protein designed to target specific cells in the body.

Specifically, cusatuzumab is a humanized monoclonal antibody that targets a protein called CD70 on the surface of certain cancer cells[2][4]. The term “humanized” means that while the antibody was originally derived from an animal (in this case, a camelid, which includes camels and llamas), it has been modified to be more similar to human antibodies. This modification helps reduce the chances of the body rejecting the drug.

What Conditions Does Cusatuzumab Treat?

Cusatuzumab is being studied primarily for the treatment of blood cancers, specifically:

  • Acute Myeloid Leukemia (AML): This is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal white blood cells that interfere with the production of normal blood cells[1][2][3][4][5].
  • Myelodysplastic Syndromes (MDS): These are a group of disorders caused by poorly formed or dysfunctional blood cells. MDS can sometimes progress to AML[3].
  • Chronic Myelomonocytic Leukemia (CMML): This is a type of cancer that affects blood-forming cells in the bone marrow[3].

Cusatuzumab is being investigated particularly for patients who are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT), which are standard treatments for these conditions[2][3][5].

How Does Cusatuzumab Work?

Cusatuzumab works by targeting the CD70 protein, which is found on the surface of many cancer cells, especially in AML[2]. When cusatuzumab binds to CD70, it triggers the body’s immune system to attack and destroy the cancer cells. This process is called antibody-dependent cell-mediated cytotoxicity (ADCC)[2].

Research has shown that over 95% of AML blasts (immature blood cells) from newly diagnosed patients express CD70 on their surface, making it a promising target for treatment[2].

Current Clinical Trials

Cusatuzumab is currently being studied in several clinical trials. These trials are designed to evaluate how well the drug works, how safe it is, and how it interacts with other treatments. Some key aspects of these trials include:

  • Dosage: Different doses of cusatuzumab are being tested, typically ranging from 10 mg/kg to 20 mg/kg, administered intravenously (through a vein)[1][2][4][5].
  • Treatment schedule: The drug is usually given every two weeks or on specific days of a treatment cycle[1][2][5].
  • Patient population: The trials focus on patients with newly diagnosed AML, MDS, or CMML who are not eligible for intensive chemotherapy[2][3][5].
  • Outcome measures: Researchers are looking at various outcomes, including overall survival, response rates, and side effects[1][2][3][4][5].

Cusatuzumab in Combination Therapy

Many of the clinical trials are studying cusatuzumab in combination with other drugs. This approach, called combination therapy, is common in cancer treatment as it can often lead to better results than using a single drug alone. The main combinations being studied are:

  • Cusatuzumab + Azacitidine: Azacitidine is a drug already approved for treating AML and MDS. It works by helping bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow[1][2][3].
  • Cusatuzumab + Venetoclax + Azacitidine: Venetoclax is another drug used in treating AML. It works by blocking a protein that helps cancer cells survive[4][5].

These combinations are being compared to standard treatments to see if adding cusatuzumab improves outcomes for patients[2][3][5].

Potential Side Effects

As with all medications, cusatuzumab may cause side effects. In the clinical trials, researchers are carefully monitoring for any adverse events. Some of the things they’re looking out for include:

  • General side effects such as fatigue, nausea, or fever
  • Changes in blood cell counts
  • Infusion-related reactions (since the drug is given intravenously)
  • Development of antibodies against the drug (anti-drug antibodies)[2][4][5]

It’s important to note that the full range of potential side effects is still being studied, and the benefits and risks of the treatment will be carefully evaluated before the drug can be approved for general use.

Future Prospects

The development of cusatuzumab represents an exciting new approach in the treatment of blood cancers. If the clinical trials show positive results, it could provide a new option for patients who currently have limited treatment choices, particularly those who are not eligible for intensive chemotherapy[2][3][5].

Researchers are particularly interested in how cusatuzumab might improve outcomes when combined with existing treatments. They are looking at whether it can help patients live longer, achieve remission (when signs of cancer disappear), or improve their quality of life[2][3][5].

While the results of these studies are still pending, cusatuzumab represents a promising area of research in the ongoing fight against blood cancers.

Aspect Details
Drug Name Cusatuzumab (also known as JNJ-74494550, ARGX-110)
Drug Type Humanized monoclonal antibody targeting CD70
Conditions Studied Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Combination Therapies Azacitidine, Venetoclax
Administration Intravenous infusion, typically 10 or 20 mg/kg on days 3 and 17 of 28-day cycles
Key Outcomes Measured Overall survival, Complete remission rate, Overall response rate, Minimal residual disease negativity, Safety and tolerability
Patient Population Newly diagnosed AML or high-risk MDS patients ineligible for intensive chemotherapy
Trial Phases Phase 1b and Phase 2 studies

FAQ

  • What is cusatuzumab? Cusatuzumab is an experimental drug that is a humanized monoclonal antibody. It targets and binds to a protein called CD70 that is found on cancer cells in AML and MDS.
  • What types of cancer is cusatuzumab being studied for? Cusatuzumab is being studied primarily for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). Some trials are also including patients with chronic myelomonocytic leukemia (CMML).
  • How is cusatuzumab given to patients in clinical trials? In the clinical trials, cusatuzumab is given as an intravenous (IV) infusion, typically at doses of 10 mg/kg or 20 mg/kg. It is often given on days 3 and 17 of each 28-day treatment cycle.
  • What other drugs is cusatuzumab being combined with in trials? Cusatuzumab is being studied in combination with azacitidine in several trials. Some studies are also evaluating it in combination with venetoclax and azacitidine together.
  • What are the main goals of the cusatuzumab clinical trials? The main goals are to determine the safety, proper dosing, and effectiveness of cusatuzumab. Trials are looking at outcomes like overall response rate, complete remission rate, survival time, and side effects in patients treated with cusatuzumab-containing regimens compared to standard treatments.

Ongoing Clinical Trials on Cusatuzumab

  • Study on Venetoclax, Azacitidine, and Cusatuzumab for Newly Diagnosed Acute Myeloid Leukemia Patients Not Suitable for Intensive Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany Spain

  • Study of Cusatuzumab and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer where the bone marrow makes abnormal white blood cells, red blood cells, or platelets. It progresses quickly if not treated.
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow does not produce enough healthy blood cells. It can progress to AML in some cases.
  • CD70: A protein found on some cancer cells that cusatuzumab targets and binds to.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Cusatuzumab is this type of drug.
  • Azacitidine: A chemotherapy drug often used to treat MDS and AML. It is being combined with cusatuzumab in some trials.
  • Venetoclax: A targeted therapy drug that blocks a protein called BCL-2 in cancer cells. Some trials are studying it with cusatuzumab and azacitidine.
  • Complete Remission (CR): When there is no evidence of disease and blood counts have returned to normal after treatment.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain after treatment, often detectable only by very sensitive tests.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure where healthy blood-forming stem cells are used to replace diseased bone marrow. Some trials are looking at cusatuzumab as a bridge to transplant.

References

  1. https://clinicaltrials.gov/study/NCT04241549
  2. https://clinicaltrials.gov/study/NCT04023526
  3. https://clinicaltrials.gov/study/NCT04264806
  4. https://clinicaltrials.gov/study/NCT04150887
  5. https://clinicaltrials.eu/trial/study-on-venetoclax-azacitidine-and-cusatuzumab-for-newly-diagnosed-acute-myeloid-leukemia-patients-not-suitable-for-intensive-therapy/